D-galactosamine/lipopolysaccharide-induced hepatotoxicity downregulates sirtuin 1 in rat liver: Role of sirtuin 1 modulation in hepatoprotection

Physiological Research

Volumn 63, Issue 5, 2014, Pages 615-623

  Kemelo, M K ^a   Wojnarova L ^a   Kutinova Canova N ^a   Farghali, H ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

D galactosamine lipopolysaccharide; EX 527; Hepatotoxicity; Resveratrol; SIRT1

Indexed keywords

6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE; ANTIOXIDANT; CARBAZOLE DERIVATIVE; ENZYME INHIBITOR; GALACTOSAMINE; LIPOPOLYSACCHARIDE; RESVERATROL; SIRT1 PROTEIN, RAT; SIRTUIN 1; STILBENE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROTECTION; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; ENZYMOLOGY; LIPID PEROXIDATION; LIVER; MALE; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; CARBAZOLES; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG-INDUCED LIVER INJURY; ENZYME INHIBITORS; GALACTOSAMINE; LIPID PEROXIDATION; LIPOPOLYSACCHARIDES; LIVER; MALE; RATS, WISTAR; SIRTUIN 1; STILBENES;

EID: 84920008183     PISSN: 08628408     EISSN: 18029973     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. ALCORN JM, FIERER J, CHOJKIER M: The acute phase response protects mice from D-galactosamine sensitization to endotoxin and tumor necrosis factor-alpha. Hepatology 15: 122-129, 1992.
2. ARA C, KIRIMLIOGLU H, KARABULUT AB, COBAN S, AY S, HARPUTLUOGLU M, KIRIMLIOGLU V, YILMAZ S: Protective effect of resveratrol against oxidative stress in cholestasis. J Surg Res 127: 112-117, 2005.
3. BANSAL AK, BANSAL M, SONI G, BHATNAGAR D: Protective role of Vitamin E pre-treatment on Nnitrosodiethylamine induced oxidative stress in rat liver. Chem Biol Interact 156: 101-111, 2005.
4. BAUR JA, MAI A, GUARENTE L: Revelations into resveratrol's mechanism. Nat Med 18: 500-501, 2012.
5. BEHER D, WU J, CUMINE S, KIM KW, LU SC, ATANGAN L, WANG M: Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74: 619-624, 2009.
6. BIASUTTO L, MATTAREI A, ZORATTI M: Resveratrol and health: the starting point. Chembiochem 13: 1256-1259, 2012.
7. BLANDER G, GUARENTE L: The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417-435, 2004.
8. BRADHAM CA, PLÜMPE J, MANNS MP, BRENNER DA, TRAUTWEIN C: Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol 275: G387-G392-2008, .
9. BRUNET A, SWEENEY LB, STURGILL JF, CHUA KF, GREER PL, LIN Y, TRAN H, ROSS SE, MOSTOSLAVSKY R, COHEN HY, HU LS, CHENG HL, JEDRYCHOWSKI MP, GYGI SP, SINCLAIR DA, ALT FW, GREENBERG ME: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015, 2004.
10. CENGIZ N, KAVAK S, GÜZEL A, OZBEK H, BEKTAŞ H, HIM A, ERDOĞAN E, BALAHOROĞLU R: Investigation of the hepatoprotective effects of Sesame (Sesamumindicum L.) in carbon tetrachloride-induced liver toxicity. J Membr Biol 246: 1-6, 2013.
11. CENTENO-BAEZ C, DALLAIRE P, MARETTE A: Resveratrol inhibition of inducible nitric oxide synthase in skeletal muscle involves AMPK but not SIRT1. Am J Physiol 301: E922-E930-2011, .
12. CERNÝ D, LEKIĆ N, VÁŇOVÁ K, MUCHOVÁ L, HOŘÍNEK A, KMONÍČKOVÁ E, ZÍDEK Z, KAMENÍKOVÁ L, FARGHALI H: Hepatoprotective effect of curcumin in lipopolysaccharide/-galactosamine model of liver injury in rats: relationship to HO-1/CO antioxidant system. Fitoterapia 82: 786-791, 2011.
13. CHAN AC, FAN ST, LO CM, LIU CL, CHAN SC, NG KK, YONG BH, CHIU A, LAM BK: Liver transplantation for acute-on-chronic liver failure. Hepatol Int 3: 571-581, 2009.
14. CHEN ML, YI L, JIN X, LIANG XY, ZHOU Y, ZHANG T, XIE Q, ZHOU X, CHANG H, FU YJ, ZHU JD, ZHANG QY, MI MT: Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway. Autophagy 9: 2033-45. 2013.
15. CHOI SE, KEMPER JK: Regulation of SIRT1 by MicroRNAs. Mol Cells 36: 385-392, 2013.
16. DUFOUR DR, LOTT JA, NOLTE FS, GRETCH DR, KOFF RS, SEEFF LB: Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem 46: 2027-2049, 2000.
17. FARGHALI H, CERNÝ D, KAMENÍKOVÁ L, MARTÍNEK J, HORÍNEK A, KMONÍCKOVÁ E, ZÍDEK Z:Resveratrol attenuates lipopolysaccharide-induced hepatitis in D-galactosamine sensitized rats: role of nitric oxide synthase 2 and heme oxygenase-1. Nitric Oxide 21: 216-225, 2009.
18. FARGHALI H, KUTINOVÁ CANOVÁ N, LEKIĆ N: Resveratrol and related compounds as antioxidants with an allosteric mechanism of action in epigenetic drug targets. Physiol Res 62: 1-13, 2013.
19. GERTZ M, FISCHER F, NGUYEN GT, LAKSHMINARASIMHAN M, SCHUTKOWSKI M, WEYAND M, STEEGBORN C: Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism. Proc Natl Acad Sci USA 110: E2772-E2781-2013, .
20. GOTTHARDT D, RIEDIGER C, WEISS KH, ENCKE J, SCHEMMER P, SCHMIDT J, SAUER P: Fulminant hepatic failure: etiology and indications for liver transplantation. Nephrol Dial Transplant 22: 5-8, 2007.
21. HADDAD Y, VALLERAND D, BRAULT A, HADDAD PS: Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med 2011: article ID 647903, 2011.
22. HASEGAWA K, WAKINO S, YOSHIOKA K, TATEMATSU S, HARA Y, MINAKUCHI H, WASHIDA N, TOKUYAMA H, HAYASHI K, ITOH H: Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun 372: 51-56, 2008.
23. HIRONO S, NAKAMA T, TSUBOUCHI H: Molecular mechanisms of D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice and the effects of therapeutic agents. In: Trends in Gastroenterology and Hepatology: Millennium 2000. Niigata, 2001, pp 59-62.
24. HONG JY, LEBOFSKY M, FARHOOD A, JAESCHKE H: Oxidant stress-induced liver injury in vivo: role of apoptosis, oncotic necrosis, and c-Jun NH2-terminal kinase activation. Am J Physiol 296: G572-G581-2009, .
25. HOWITZ KT, BITTERMAN KJ, COHEN HY, LAMMING DW, LAVU S, WOOD JG, ZIPKIN RE, CHUNG P, KISIELEWSKI A, ZHANG LL, SCHERER B, SINCLAIR DA: Small molecule activators of Sirtuins extend Saccharomycetescerevisiae lifespan. Nature 425: 191-196, 2003.
26. HSUEH CJ, WANG JH, DAI L, LIU CC: Determination of alanine aminotransferase with an electrochemical nano Ir-C biosensor for the screening of liver diseases. Biosensors 1: 107-117, 2011.
27. JACKSON MD, DENU JM: Structural identification of 2'- and 3'-O-acetyl-ADP-ribose as novel metabolites derived from the Sir2 family of beta -NAD+-dependent histone/protein deacetylases. J Biol Chem 277: 18535-18544, 2002.
28. KOSAI K, MATSUMOTO K, FUNAKOSHI H, NAKAMURA T: Hepatocyte growth factor prevents endotoxininduced lethal hepatic failure in mice. Hepatology 30: 151-159, 1999.
29. LEIST M, GANTNER F, BOHLINGER I, TIEGS G, GERMANN PG, WENDEL A: Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am J Pathol 146: 1220-1234, 1995.
30. LEKIĆ N, CERNÝ D, HOŘÍNEK A, PROVAZNÍK Z, MARTÍNEK J, FARGHALI H: Differential oxidative stress responses to D-galactosamine-lipopolysaccharide hepatotoxicity based on real time PCR analysis of selected oxidant/antioxidant and apoptotic gene expressions in rat. Physiol Res 60: 549-558, 2011.
31. LEKIĆ N, CANOVÁ NK, HOŘÍNEK A, FARGHALI H: The involvement of hemeoxygenase 1 but not nitric oxide synthase 2 in a hepatoprotective action of quercetin in lipopolysaccharide-induced hepatotoxicity of Dgalactosamine sensitized rats. Fitoterapi 87: 20-26, 2013.
32. MAYER M: Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 46: 1723-1727, 2000.
33. MCDOWELL TORRES D, STEVENS RD, GURAKAR A: acute liver failure: a management challenge for the practicing gastroenterologist. Gastroenterol Hepatol (NY) 6: 444-450, 2010.
34. MORIKAWA A, KOIDE N, SUGIYAMA T, MU MM, HASSAN F, ISLAM S, ITO H, MORI I, YOSHIDA T, YOKOCHI T: The enhancing action of D-galactosamine on lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophage cells. FEMS Immunol Med Microbiol 41: 211-218, 2004.
35. NAPPER AD, HIXON J, MCDONAGH T, KEAVEY K, PONS JF, BARKER J, YAU WT, AMOUZEGH P, FLEGG A, HAMELIN E, THOMAS RJ, KATES M, JONES S, NAVIA MA, SAUNDERS JO, DISTEFANO PS, CURTIS R: Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 48: 8045-8054, 2005.
36. NIKI E: Lipid peroxidation products as oxidative stress biomarkers. Biofactors 34: 171-180, 2008.
37. PACHER P, BECKMAN JS, LIAUDET L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.
38. PARK SJ, AHMAD F, PHILP A, BAAR K, WILLIAMS T, LUO H, KE H, REHMANN H, TAUSSIG R, BROWN AL, KIM MK, BEAVEN MA, BURGIN AB, MANGANIELLO V, CHUNG JH: Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421-433, 2012.
39. PRADEEP HA, KHAN S, RAVIKUMAR K, AHMED MF, RAO MS, KIRANMAI M, REDDY DS, AHAMED SR, IBRAHIM M: Hepatoprotective evaluation of Anogeissus latifolia: in vitro and in vivo studies. World J Gastroenterol 15: 4816-4822, 2009.
40. RIVERA H, SHIBAYAMA M, TSUTSUMI V, PEREZ-ALVAREZ V, MURIEL P: Resveratrol and trimethylated resveratrol protect from acute liver damage induced by CCl4 in the rat. J Appl Toxicol 28: 147-155, 2008.
41. RUDERMAN NB, XU XJ, NELSON L, CACICEDO JM, SAHA AK: AMPK and SIRT1: a long-standing partnership? Am J Physiol 298: E751-E760, 2010.
42. RUSSO FP, PAROLA M: Stem and progenitor cells in liver regeneration and repair. Cytotherapy 13: 135-144, 2011.
43. SILVERSTEIN R: D-galactosamine lethality model: scope and limitations. J Endotoxin Res 10: 147-162, 2004.
44. SMITH M, MURPHY P: A historic opportunity to improve organ donation rates in the UK. Br J Anaesth 100: 735-737, 2008.
45. SOLOMON JM, PASUPULETI R, XU L, MCDONAGH T, CURTIS R, DISTEFANO PS, HUBER LJ: Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 26: 28-38, 2006.
46. SZABÓ C, OHSHIMA H: DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide 1: 373-385, 1997.
47. TANNO M, KUNO A, YANO T, MIURA T, HISAHARA S, ISHIKAWA S, SHIMAMOTO K, HORIO Y: Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 285: 8375-8382, 2010.
48. UCHIKURA K, WADA T, HOSHINO S, NAGAKAWA Y, AIKO T, BULKLEY GB, KLEIN AS, SUN Z:Lipopolysaccharides induced increases in Fas ligand expression by Kupffer cells via mechanisms dependent on reactive oxygen species. Am J Physiol 287: G620-G626, 2004.
49. VASKO R, XAVIER S, CHEN J, LIN CH, RATLIFF B, RABADI M, MAIZEL J, TANOKUCHI R, ZHANG F, CAO J, GOLIGORSKY MS: Endothelial sirtuin 1 deficiency perpetrates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence. J Am Soc Nephrol 25: 276-291, 2014.
50. WANG P, DU B, YIN W, WANG X, ZHU W: Resveratrol attenuates CoCl2-induced cochlear hair cell damage through upregulation of Sirtuin1 and NF-κB deacetylation. PLoS One 8: e80854-2013, .
51. WANG RH, KIM HS, XIAO C, XU X, GAVRILOVA O, DENG CX: Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest 121: 4477-4490, 2011.
52. WEN D, HUANG X, ZHANG M, ZHANG L, CHEN J, GU Y, HAO CM: Resveratrol attenuates diabetic nephropathy via modulating angiogenesis. PLoS One 8: e82336, 2013.
53. YAMAKUCHI M: MicroRNA regulation of SIRT1. Front Physiol 3: Article 68, 2012.
54. YEUNG F, HOBERG JE, RAMSEY CS, KELLER MD, JONES DR, FRYE RA, MAYO MW: Modulation of NF-κBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369-2380, 2004.